Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

A number of factors, such as the surging prevalence of osteoporosis in females, growing awareness about the disease and its treatment, rising investments by market players for the development of drugs, and increasing expenditure on healthcare, are projected to boost the growth of the osteoporosis drugs market at a CAGR of 3.8% in the forecast period (2016–2022). At this growth rate, the market size is expected to reach $11,482.1 million by 2022 from $8,835.4 million in 2015.

Read the full report Osteoporosis Drugs Market

The key trend being observed in the market is the rising awareness among people across the world about osteoporosis. The awareness is mainly increasing due to the initiatives being taken by government and private organizations, such as seminars, conferences, workshops, campaigns, and programs. For instance, an association working in the field of osteoporosis in the U.S., the National Osteoporosis Foundation, observes May as the National Osteoporosis Month, to improve the awareness about the complications, effects, and treatment of this disease.

The primary factor improving the osteoporosis drugs market growth prospects is the increasing prevalence of osteoporosis. According to the World Health Organization (WHO) data, around 55% of the population currently lives in urban areas, globally, with the share expected to reach about 68% by 2050. Urbanization leads to an unhealthy lifestyle, which negatively impacts bone health. This results in a large number of individuals suffering from the disease; therefore, the demand for osteoporosis drugs will increase during the forecast period for the treatment of this condition.

The drug class segment of the osteoporosis drugs market is categorized into parathyroid hormone therapy, bisphosphonates, selective estrogen receptor modulator (SERM), calcitonin, rank ligand inhibitor, and others. Among these, the bisphosphonates category accounted for the largest share in 2015 in the market. On the other hand, the rank ligand inhibitor category is projected to observe the highest CAGR in the coming years.


Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe